EGFR mutations

临床试验

计划入组 121 人 · 首次发布于 2012 年 12 月 21 日

暂停

NCT05421936

Osimertinib for NSCLC With Uncommon EGFR Mutations

计划入组 100 人 · 首次发布于 2022 年 6 月 16 日

招募中

NCT04811001

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

计划入组 170 人 · 首次发布于 2021 年 3 月 23 日

药物

查看全部 269 →

Small Molecule

Approved

Afatinib(Gilotrif, Giotrif)

相关疾病：Metastatic Non-Small Cell Lung Cancer, Refractory, metastatic squamous cell Non-small cell lung cancer

C₂₄H₂₅ClFN₅O₃ · Rx

Small Molecule

Approved

Mobocertinib(Exkivity)

相关疾病：Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer

C₃₂H₃₉N₇O₄ · Rx

EGFR antagonists

机构

查看全部 4 →

SpringWorks Therapeutics

United States

Cogent Biosciences

United States

IDEAYA Biosciences

United States

资讯

查看全部 3322 →

9个月前

ArriVent Initiates Pivotal Phase 3 ALPACCA Trial for Firmonertinib in EGFR PACC Mutant NSCLC

去年

Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations

去年

临床试验

INHERIT EGFR - Studying Germline EGFR Mutations

Osimertinib for NSCLC With Uncommon EGFR Mutations

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

药物

Afatinib(Gilotrif, Giotrif)

Mobocertinib(Exkivity)

EGFR antagonists

机构

SpringWorks Therapeutics

Cogent Biosciences

IDEAYA Biosciences

资讯

ArriVent Initiates Pivotal Phase 3 ALPACCA Trial for Firmonertinib in EGFR PACC Mutant NSCLC

Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations

BlossomHill Therapeutics to Present Novel OMNI-EGFR Inhibitor BH-30643 at AACR 2025 for NSCLC Treatment